185 related articles for article (PubMed ID: 16565241)
1. Statins and renal diseases: from primary prevention to renal replacement therapy.
D'Amico G
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S148-52. PubMed ID: 16565241
[TBL] [Abstract][Full Text] [Related]
2. Statins in nephrotic syndrome: a new weapon against tissue injury.
Buemi M; Nostro L; Crascì E; Barillà A; Cosentini V; Aloisi C; Sofi T; Campo S; Frisina N
Med Res Rev; 2005 Nov; 25(6):587-609. PubMed ID: 16075407
[TBL] [Abstract][Full Text] [Related]
3. Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins.
Wheeler DC
J Nephrol; 2001; 14 Suppl 4():S70-5. PubMed ID: 11798150
[TBL] [Abstract][Full Text] [Related]
4. [Dyslipidemia and the risk of kidney disease].
Ligabue G; Cavazzini F; Albertazzi A
G Ital Nefrol; 2007; 24 Suppl 38():8-12. PubMed ID: 17922441
[TBL] [Abstract][Full Text] [Related]
5. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
Vaziri ND
J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
[TBL] [Abstract][Full Text] [Related]
6. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
Robinson JG
Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
[TBL] [Abstract][Full Text] [Related]
7. The dyslipidemia of chronic renal disease: effects of statin therapy.
Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
[TBL] [Abstract][Full Text] [Related]
8. Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients?
Steffens S; Mach F
Nat Clin Pract Nephrol; 2006 Jul; 2(7):378-87. PubMed ID: 16932466
[TBL] [Abstract][Full Text] [Related]
9. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
Geiss HC; Otto C; Parhofer KG
Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
[TBL] [Abstract][Full Text] [Related]
10. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
11. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
Cui Y; Watson DJ; Girman CJ; Shapiro DR; Gotto AM; Hiserote P; Clearfield MB
Am J Cardiol; 2009 Sep; 104(6):829-34. PubMed ID: 19733719
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with statins and omega-3 fatty acids.
Nambi V; Ballantyne CM
Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
[TBL] [Abstract][Full Text] [Related]
13. Statin therapy in patients with chronic kidney disease: to use or not to use.
Steinmetz OM; Panzer U; Stahl RA; Wenzel UO
Eur J Clin Invest; 2006 Aug; 36(8):519-27. PubMed ID: 16893373
[TBL] [Abstract][Full Text] [Related]
14. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
15. Statin pleiotropy against renal injury.
Kostapanos MS; Liberopoulos EN; Elisaf MS
J Cardiometab Syndr; 2009; 4(1):E4-9. PubMed ID: 19245508
[TBL] [Abstract][Full Text] [Related]
16. Pleiotropic effects and cholesterol-lowering therapy.
Shaw SM; Fildes JE; Yonan N; Williams SG
Cardiology; 2009; 112(1):4-12. PubMed ID: 18577880
[TBL] [Abstract][Full Text] [Related]
17. Lipid abnormalities in chronic renal failure, nephrotic syndrome and dialysis.
Kes P
Acta Med Croatica; 2001; 55(4-5):177-86. PubMed ID: 12398021
[TBL] [Abstract][Full Text] [Related]
18. Effects of statins on renal function.
Agarwal R
Am J Cardiol; 2006 Mar; 97(5):748-55. PubMed ID: 16490450
[TBL] [Abstract][Full Text] [Related]
19. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
